Merck has a new drug med coming this May. IDVYNSO is a combination of doravirine & islatravir. It is not recommended for people currently on some meds, such as lamivudine. It could lower the med's effectiveness & cause possible toxicity. It's unclear how long a person would have to off lamivudine before they could start this. This is the only non-INSTI 2 drug med without tenofovir given orally currently available.
This could be a great new option for people. These are newer meds comprising a new combo. Islatravir is the only med in a new category of NRTTIs. This a significant step.
Give this piece a read.
Take care.
Cya...
No comments:
Post a Comment